Louisiana Funds

Louisiana Funds is a venture capital firm established in 2003 and headquartered in Baton Rouge, Louisiana. The firm specializes in early-stage investments, primarily targeting companies in the life sciences sector, including pharmaceuticals and biotechnology. Additionally, Louisiana Funds focuses on agritechnology and information technology, seeking to support high-technology firms within these industries. By concentrating on Louisiana-based enterprises, the firm aims to foster regional economic growth and innovation.

Richard Babb

Managing Director

Joseph F. Lovett

Managing Director

11 past transactions

Qure4u

Series A in 2018
Qure4u Inc. is a healthcare technology company that specializes in developing a comprehensive patient engagement and remote monitoring platform. Founded in 2011 and headquartered in Bradenton, Florida, Qure4u’s platform facilitates seamless connections among patients, healthcare providers, labs, pharmacies, and insurers, ensuring that critical medical information—such as diagnoses, allergies, medications, lab results, and vital signs—is readily accessible. The platform enhances the overall patient experience by allowing individuals to prepare for appointments, monitor their health status, and communicate securely with their providers through telehealth and messaging features. Additionally, the software streamlines administrative processes, enabling healthcare staff to effectively manage patient interactions, identify those at risk, and improve treatment outcomes while reducing unnecessary hospital visits.

Omnidek

Seed Round in 2017
Omnidek is an enterprise smart data content management platform that enables businesses of any size to create corporate forms, portals, workflows, and analytics within a unified mobile and web interface. The platform streamlines business process management by eliminating the need for paper, files, folders, and spreadsheets, thereby reducing administrative burdens. It features a chat-style inbox that enhances integrated workflows, allowing for efficient communication and collaboration among team members. By consolidating third-party applications, Omnidek simplifies the rollout of technology across enterprises, facilitating data-driven decision-making and improving overall operational efficiency.

Servato

Venture Round in 2015
Servato Corporation specializes in developing Active Battery Management Systems (ABMS) that manage, monitor, and charge lead-acid batteries used for backup power in industrial environments. The company offers a Platform-as-a-Service solution aimed at remote direct current (DC) power management across various industries. By utilizing an innovative charging algorithm, a management appliance, and cloud-based visualization software, Servato enables organizations to gain enhanced insight and control over their distributed DC power assets. Founded in 2014 and headquartered in New Orleans, Louisiana, Servato's technology ensures reliable battery management, allowing companies to maintain uninterrupted power supply for critical operations.

Embera NeuroTherapeutics

Series A in 2015
Embera NeuroTherapeutics, Inc. is a pharmaceutical company based in Sudbury, Massachusetts, focused on developing innovative treatments for smoking cessation, cocaine dependence, and other addictions, areas that currently lack effective drug therapies. Founded in 2005, the company is advancing EMB-001, a novel addiction treatment that combines the benzodiazepine oxazepam with metyrapone, a cortisol synthesis inhibitor. This treatment targets the stress response system and specific brain functions associated with craving and relapse, aiming to modulate various stress-related pathways to alleviate the cravings that drive addictive behaviors. Embera NeuroTherapeutics is committed to addressing the significant challenges faced by individuals struggling with addiction by providing effective therapeutic options.

Embera NeuroTherapeutics

Series A in 2011
Embera NeuroTherapeutics, Inc. is a pharmaceutical company based in Sudbury, Massachusetts, focused on developing innovative treatments for smoking cessation, cocaine dependence, and other addictions, areas that currently lack effective drug therapies. Founded in 2005, the company is advancing EMB-001, a novel addiction treatment that combines the benzodiazepine oxazepam with metyrapone, a cortisol synthesis inhibitor. This treatment targets the stress response system and specific brain functions associated with craving and relapse, aiming to modulate various stress-related pathways to alleviate the cravings that drive addictive behaviors. Embera NeuroTherapeutics is committed to addressing the significant challenges faced by individuals struggling with addiction by providing effective therapeutic options.

Esperance Pharmaceuticals

Series B in 2011
Esperance Pharmaceuticals Inc. is a biotechnology company based in Houston, Texas, focused on developing targeted anticancer drugs for women with ovarian and breast cancer. The company's key product, EP-100, is an oncolytic peptide designed to selectively bind to receptors for luteinizing hormone releasing hormone (LHRH) found on cancer cells, enabling it to destroy these cells while sparing normal tissue. This innovative approach allows the drug to effectively target both dividing and non-dividing cancer cells, including those resistant to traditional chemotherapy. Esperance has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, further enhancing its commitment to advancing cancer treatment. The company was incorporated in 2005 and is dedicated to improving outcomes for patients through its novel therapeutic strategies.

Esperance Pharmaceuticals

Series A in 2008
Esperance Pharmaceuticals Inc. is a biotechnology company based in Houston, Texas, focused on developing targeted anticancer drugs for women with ovarian and breast cancer. The company's key product, EP-100, is an oncolytic peptide designed to selectively bind to receptors for luteinizing hormone releasing hormone (LHRH) found on cancer cells, enabling it to destroy these cells while sparing normal tissue. This innovative approach allows the drug to effectively target both dividing and non-dividing cancer cells, including those resistant to traditional chemotherapy. Esperance has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, further enhancing its commitment to advancing cancer treatment. The company was incorporated in 2005 and is dedicated to improving outcomes for patients through its novel therapeutic strategies.

Portico Learning Solutions

Venture Round in 2008
At Portico, they have focused on providing eLearning solutions to government and corporate entities since 1998. They specialize in courseware management and custom eLearning courseware development, and have implemented both their courseware and their learning management systems successfully in a wide range of technical environments. Their company currently provides eLearning to many companies spanning many industries, worldwide. Their approach to every solution is to match training initiatives to their clients' business objectives and strategies, enabling them to add value to their enterprise.

Dowley Security Systems

Series B in 2007
Dowley Security Systems, Inc. provides electronic security and network integration solutions to critical infrastructure and commercial markets. It specializes in the design, installation, service, and support of security solutions for industrial, government, and commercial organizations. The company’s services include access control, intrusion detection/monitoring, video surveillance, fire alarm and fire suppression, locksmithing, network infrastructure and integration, project management, service on-call, and budgeted maintenance. Dowley SecuSystems, Inc. was formerly known as Infrastruct Security, Inc. and changed its name to Dowley Security Systems, Inc. in April 2010. The company was founded in 1986 and is based in Houston, Texas with locations in Oklahoma City and Tulsa, Oklahoma.

Flying Fish Creative Services

Venture Round in 2006
Flying Fish Creative Services is a commercial art studio. offering illustration, design, retouching, digital imaging, and photographic services. They focused on courseware management. They delivers creative solutions to small businesses, corporate clients and local non-profits.

Primorigen Biosciences

Series A in 2006
Primorigen Biosciences Inc. specializes in the development of protein and cell-based assay systems aimed at cellular characterization and preclinical research. The company offers a range of products, including cell culture matrices, antibodies, recombinant proteins, and primary neuronal and mesenchymal stem cells. Founded in 2005 and located in Madison, Wisconsin, Primorigen Biosciences focuses on delivering innovative and cost-effective solutions for stem cell maintenance, proliferation, differentiation, and large-scale production. As of August 2019, it operates as a subsidiary of Nucleus Biologics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.